Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2: a cohort analysis

Daniel Prieto-Alhambra (daniel.prietoalhambra@ndoms.ox.ac.uk)
1. Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, UK
2. Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands

Eduardo Hermosilla
1. Direcció assistencial d'Atenció Primària i a la Comunitat, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain
2. Idiap Jordi Gol, Uni

Ermengol Coma
1. Direcció assistencial d'Atenció Primària i a la Comunitat, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain

Junqing Xie
https://orcid.org/0000-0001-8000-3321

Shuo Feng
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK

Carmen Cabezas
Public Health Secretariat, Department of Health, Generalitat de Catalunya, Barcelona, Spain

Leonardo Méndez-Boo
Institut Català de la Salut (ICS), Generalitat de Catalunya
https://orcid.org/0000-0002-9215-4378

Francesc Fina
Direcció assistencial d'Atenció Primària i a la Comunitat, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain

Elisabet Ballo
Direcció assistencial d'Atenció Primària i a la Comunitat, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain

Montserrat Martínez
Public Health Secretariat, Department of Health, Generalitat de Catalunya, Barcelona, Spain

Manuel Medina-Peralta
Direcció assistencial d'Atenció Primària i a la Comunitat, Institut Català de la Salut (ICS), Generalitat de Catalunya, Barcelona, Spain

Josep Maria Argimon
Public Health Secretariat, Department of Health, Generalitat de Catalunya, Barcelona, Spain
Abstract

Small trials have suggested that heterologous vaccination with first-dose ChAdOx1 and second-dose BNT162b2 may generate a better immune response than homologous vaccination with two doses of ChAdOx1. We used linked data from Catalonia (Spain), where those aged <60 who received a first dose of ChAdOx1 could choose between ChAdOx1 and BNT162b2 for their second dose. Comparable cohorts were obtained after exact-matching 14,325/17,849 (80.3%) people receiving heterologous vaccination to 14,325/149,386 (9.6%) receiving homologous vaccination by age, sex, region, and date of second dose. Of these, 238 (1.7%) in the heterologous and 389 (2.7%) in the homologous groups developed COVID-19 between 1st June 2021 and 11th October 2021. The resulting hazard ratio (95% confidence interval) was 0.61 [0.52-0.71], favouring heterologous vaccination, with a Number Needed to Treat of 94.9 [71.8 - 139.8]. The two groups had similar testing rates and safety outcomes. Sensitivity and negative control outcome analyses confirmed these findings. In conclusion, we demonstrate that a heterologous vaccination schedule with ChAdOx1 followed by BNT162b2 was more efficacious than and similarly safe to homologous vaccination with two doses of ChAdOx1. Most of the infections in our study occurred when Delta was the predominant SARS-CoV-2 variant in Spain. These data agree with previous phase 2 randomised trials.

Main Text

Rationale

The rapid development of COVID-19 vaccines has allowed remarkable progress in the global fight against the SARS-CoV-2 pandemic. As of 27th October 2021, around half of the world's population had received at least one dose of a COVID-19 vaccine. While 15 vaccines have been approved for use by at least one authority, most countries have received more than four approved vaccines\(^1\).

The ChAdOx nCoV-19 (ChAdOx1) and BNT162b2 vaccines were among the first approved by the European Medicines Agency for emergency use in the European Union. Both vaccines were tested in large phase 3 randomised controlled trials and found to be highly effective against symptomatic SARS-CoV-2 infection when given as two doses\(^2-5\). Follow-up studies have demonstrated their clinical effectiveness against severe disease, including preventing hospitalisations and mortality, overall\(^6,7\) and in previously under-researched populations\(^8\).

Spanish guidelines initially recommended the use of ChAdOx1 for people aged younger than 60 years due to the under-representation of elderly people in the initial pivotal trials\(^2\). Key workers were targeted in this initial stage to maximise the impact of vaccination on community transmission\(^9\). Despite their efficacy, reports of thrombotic events after the first dose of adenovirus-based COVID-19 vaccines led to recommendations for heterologous vaccination for those vaccinated with a first dose of ChAdOx1, i.e., many European authorities recommended the use of BNT162b2 for second doses to avoid further exposure to ChAdOx1. A small randomised controlled trial was rapidly conducted that demonstrated better immunogenicity from heterologous vaccination in Spain\(^10\), but larger studies on clinical effectiveness and safety are urgently needed\(^11\).
The Spanish authorities allowed citizens previously vaccinated with a first dose of ChAdOx1 to choose between ChAdOx1 and BNT162b2 for their second dose. The majority chose homologous vaccination with two doses of ChAdOx1. In the absence of phase 3/4 randomised controlled trials, this created a natural experiment for studying the comparative safety and effectiveness of these two vaccination schedules. We leveraged routinely collected health data, including electronic medical records linked to vaccination data and laboratory tests, to study the comparative effectiveness and safety of homologous (two-dose ChAdOx1) and heterologous (ChadOx1 followed by BNT162b2) vaccination.

**Comparative effectiveness**

Of 167,235 eligible people, 17,849 (10.7%) chose heterologous vaccination and 149,386 (89.3%) chose homologous vaccination. Figure 1 shows the inclusion/exclusion steps used to identify the study participants. For primary analyses, 14,325/17,849 (80.3%) people in the heterologous group were matched to 14,325/149,386 (9.6%) in the homologous group vaccinated with their second dose on the same date (+/- 2 days). The resulting cohorts were comparable in terms of all observed demographics, comorbidity, medicine use, area of residence, and socio-economic status (Supplementary Figure 1). Exact matching ensured the same average (SD) age (42.2 (9.6) years) and proportion of female participants (62.5%) in the two groups. A comparable proportion lived in the most socio-economically deprived (15.8% heterologous vs 15.9% homologous) and rural (19.4% heterologous vs 19.5% homologous) areas of the country (Table 1).

Study participants received their second doses between 27th April 2021 and 8th October 2021. Second doses occurred on the same date for 8,742 (61.0%) matched pairs, 1 day apart (before/after) for 4,302 (30.0%) pairs, and 2 days apart for the remaining 1,281 (9.0%) pairs. Test rates were similar in the matched cohorts, with 3,169 (22.1%) people on the heterologous schedule and 3,268 (22.8%) on the homologous schedule tested at least once during the study period. The average (SD) number of tests for heterologous and homologous groups was 0.49 (1.26) vs 0.51 (1.27) overall and 2.22 (1.81) vs 2.22 (1.82) among those tested at least once during follow-up respectively. Table 2 shows number, type of test (lateral flow test (LFT) vs polymerase chain reaction (PCR) test), and test incidence rates stratified by vaccination schedule. The incident rate ratio [95% confidence interval] of testing for heterologous versus homologous vaccination was 1.00 [0.94-1.07]. Figure 2 shows that the matched cohorts had similar timings for vaccination and testing over time.

Between 1st June and 11th October 2021, SARS-CoV-2 infections were recorded for 238 (1.66%) people in the heterologous group, equivalent to an incidence rate of 0.13/1,000 person-years, and 389 (2.72%) people in the homologous group, equivalent to an incidence rate of 0.21/1,000 person-years. These rates are equivalent to a hazard ratio of 0.61 [0.52- 0.71], favouring heterologous vaccination (Figure 3 and Table 2). This was equivalent to an absolute risk reduction (ARR) of 0.011 [0.007-0.014] and a Number Needed to Treat of 94.9 [71.8-139.8] in the study period.

No hospital admissions with COVID-19 were identified in the heterologous group, compared with 4 (0.03%) hospitalisations in the homologous group. No deaths were seen in either group.

**Safety and sensitivity analyses**
Primary analyses of 14,325 people per group found only one venous thromboembolism event (0.007%) and one venous thromboembolism with thrombocytopenia event (0.007%), both in the heterologous group. No myopericarditis events were seen in either group (Table 3).

Back pain episodes were used as a negative control outcome. They were recorded at similar frequencies in the two groups, with 196 events in the heterologous group and 170 in the homologous group. These rates are equivalent to a hazard ratio of 1.15 [0.94-1.42] (Supplementary Figure 2).

Sensitivity analyses were conducted using 1:2 and 1:5 exact matching, resulting in 12,512 people with heterologous vaccination matched to 25,024 people with homologous vaccination and 8,569 matched to 42,845, respectively. The hazard ratios for SARS-CoV-2 infection were comparable to those in the primary analysis: 0.60 [0.51-0.70] in the 1:2 and 0.56 [0.47-0.67] in the 1:5 matched cohorts. No safety concerns were identified in these larger cohorts, with only one additional safety event of myopericarditis identified in the homologous vaccination group for 1:5 matching (Table 3).

**Discussion**

**Key findings**

This is the first report to date comparing the safety and effectiveness of homologous vaccination against COVID-19 with two-dose ChAdOx1 and heterologous vaccination with first-dose ChAdOx1 and second-dose BNT162b2. Our primary analysis included over 28,000 people, over 14,000 per group, exactly matched on age, sex, region, and date of second-dose vaccination. In this rich linked cohort, we found a 40% relative risk reduction of SARS-CoV-2 infection (primary outcome) among those on the heterologous vaccination schedule compared with those on the homologous vaccination schedule, despite similar testing rates in the two groups. A total of 95 people would need heterologous (instead of homologous) vaccination to prevent 1 additional case of COVID-19 in the study period.

No safety concerns were identified, with only one event (<0.01%) of venous thromboembolism and one event of venous thromboembolism with thrombocytopenia in the heterologous group in the main analysis. One additional event of myopericarditis was observed in 42,845 people receiving homologous vaccination in the 1:5 matched sensitivity analysis.

Sensitivity analyses using 1:2 and 1:5 matching increased the sample size to >37,000 and >50,000 participants respectively and confirmed the safety and effectiveness findings. The null association between vaccination schedule and our chosen negative control outcome of back pain supported the robustness of our findings, ruling out residual confounding.

**Research in context**

Our findings that heterologous vaccination was more effective than homologous vaccination against COVID-19 agrees with emerging efficacy evidence based on immunological endpoints. Two small, randomised trials have reported higher immunogenicity, characterised by humoral and cellular responses, from ChAdOx1/BNT162b2 than ChAdOx1/ChAdOx1\textsuperscript{10,13}. These results were also corroborated by several cohort
studies\textsuperscript{14-16}. Although people vaccinated with heterologous ChAdOx1/mRNA vaccine (e.g., BNT162b2) were reported to have a 68% lower risk of symptomatic COVID-19 infection than unvaccinated people\textsuperscript{17}, little was known about the comparative effectiveness of the heterologous and homologous vaccination schedules against clinical endpoints. Our study is the first to show that heterologous ChAdOx1/BNT162b2 vaccination conferred 40% more protection against SARS-CoV-2 infection than homologous two-dose ChAdOx1 vaccination, and corroborate the potential of immunological surrogate endpoints of COVID-19 vaccines being predictive for clinical protection\textsuperscript{1819}.

Data on the post-marketing safety of heterologous vaccination schedules remain sparse, particularly for rare safety events, with most evidence from evaluations of reactogenicity\textsuperscript{10,13-15,20}. Although reactogenicity endpoints are informative for assessing potential vaccine side effects, these trials are underpowered to study rare safety outcomes. Adverse events related to the ChAdOx1 vaccine include the rare (<1/1000 to \geq 1/10 000) outcome venous thrombosis and the very rare (<1/10 000) outcome vaccine-induced immune thrombosis with thrombocytopenia syndrome\textsuperscript{21,22}. Similarly, myocarditis and pericarditis outcomes possibly associated with BNT162b2 are expected to affect around 10 to 24 people per 10 million fully vaccinated people aged \geq 30 years\textsuperscript{23}. In this study with >28,000 participants, we identified one venous thromboembolism event and one venous thromboembolism with thrombocytopenia event. The number of events did not increase much in sensitivity analyses including up to >50,000 participants, suggesting that larger studies are needed to investigate these safety signals for heterologous vaccination schedules.

\textit{Strengths and weaknesses}

Our study has several limitations. The main limitation is the observational nature of our data. However, exact matching on age, region, and date led to a good balance in all observed confounders, including socio-demographics, comorbidity, and medicines use. Our analysis of a negative control outcome (back pain) suggested comparability of the matched cohorts, including unobserved covariates.

As most of our participants were middle-aged adults aged less than 60 years old, our risk-benefit assessment may not be valid for younger or elderly people. Our sample size was insufficient for studying severe COVID-19 outcomes, including hospitalisation and mortality, or rare safety outcomes.

This study also has strengths. The rich, representative linked dataset used allowed a robust analysis of vaccine exposure and outcomes at speed to inform ongoing international vaccination campaigns. Catalonia has a universal healthcare system and uses a centralised, secure data ecosystem with a long track record of research and high-impact publications\textsuperscript{8,24}. The granularity of these data made it possible to control for confounding and test for residual systematic bias. Linkage to additional data sources on RT-PCR and LFT tests allowed for a comprehensive assessment of testing rates and reliable SARS-CoV-2 infection rates. The data collection period covered a time when most cases of COVID-19 in Catalonia were attributable to the Delta variant of SARS-CoV-2\textsuperscript{25}, which is still the predominant variant worldwide. Our data are therefore highly relevant for ongoing global vaccination strategies and future and current third-dose and booster campaigns.

\textbf{Conclusions}
In conclusion, by leveraging the potential of multiple data sources in parallel, our study confirmed that a heterologous vaccination schedule of ChAdOx1 and BNT162b2 was safe and provided better protection against COVID-19 infection than a homologous ChAdOx1 vaccination schedule in real-world settings experiencing the Delta variant. More research on other mixed-vaccine schedules with different prime-boost intervals are needed.

**Declarations**

**Ethical considerations and information governance**

All data was obtained from linked administrative sources after pseudonymisation in accordance with articles 6. e), 9.2. j) + 89 RGPD, and 17.2.d of the LOPD-GDD. The proposed study was evaluated and approved by the Clinical Research Ethics Committee of the IDIAP Jordi Gol with Reference 21/269-PCV. This research was based on the agreement established in Regulation 2016/679 of the European Parliament and of the Council of April 27, 2016 on Data Protection and Organic Law 3/2018 of December 5 of protection of personal data and guarantee of digital rights.

**Acknowledgements**

We acknowledge English language editing by Jennifer A de Beyer of the Centre for Statistics in Medicine, University of Oxford. We thank Luis Garcia-Eroles for assistance and support with data management regarding linked hospital admissions data for the study of safety outcomes.

**References**

1. UNICEF COVID-19 Vaccine Market Dashboard. [https://www.unicef.org/supply/covid-19-vaccine-market-dashboard](https://www.unicef.org/supply/covid-19-vaccine-market-dashboard) (2021).

2. Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* **397**, 99-111, doi:10.1016/S0140-6736(20)32661-1 (2021).

3. Voysey, M. *et al.* Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881-891, doi:10.1016/s0140-6736(21)00432-3 (2021).

4. Voysey, M. & Pollard, A. J. ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply. *Lancet* **396**, 1486-1487, doi:10.1016/S0140-6736(20)32267-4 (2020).

5. Polack, F. P. *et al.* Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *New England Journal of Medicine* **383**, 2603-2615 (2020).

6. Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* **397**, 2461-2462, doi:10.1016/s0140-6736(21)01358-1 (2021).
Haas, E. J. *et al.* Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet* **397**, 1819-1829, doi:10.1016/s0140-6736(21)00947-8 (2021).

Cabezas, C. *et al.* Associations of BNT162b2 vaccination with SARS-CoV-2 infection and hospital admission and death with covid-19 in nursing homes and healthcare workers in Catalonia: prospective cohort study. *Bmj* **374**, n1868, doi:10.1136/bmj.n1868 (2021).

Grupo de Trabajo Técnico de Vacunación COVID-19, de la Ponencia de Programa y Registro de Vacunaciones. Estrategia de vacunación frente a COVID-19 en España. 9 de febrero de 2021. https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion3_EstrategiaVacunacion.pdf.

Borobia, A. M. *et al.* Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. *The Lancet* **398**, 121–130, doi:10.1016/s0140-6736(21)01420-3 (2021).

Duarte-Salles, T. & Prieto-Alhambra, D. Heterologous vaccine regimens against COVID-19. *Lancet* **398**, 94-95, doi:10.1016/s0140-6736(21)01442-2 (2021).

Grupo de Trabajo Técnico de Vacunación COVID-19, de la Ponencia de Programa y Registro de Vacunaciones. Estrategia de vacunación frente a COVID-19 en España. 22 junio de 2021. https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion8_EstrategiaVacunacion.pdf.

Liu, X. *et al.* Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *The Lancet* **398**, 856–869, doi:10.1016/s0140-6736(21)01694-9 (2021).

Schmidt, T. *et al.* Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. *Nature Medicine* **27**, 1530–1535, doi:10.1038/s41591-021-01464-w (2021).

Hillus, D. *et al.* Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. *Lancet Respir Med* **9**, 1255-1265, doi:10.1016/s2213-2600(21)00357-x (2021).

Tenbusch, M. *et al.* Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. *Lancet Infect Dis* **21**, 1212-1213, doi:10.1016/s1473-3099(21)00420-5 (2021).

Nordström, P., Ballin, M. & Nordström, A. Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. *The Lancet Regional Health – Europe* **0**, 100249, doi:10.1016/j.lanepe.2021.100249 (2021).
18 Jin, P., Li, J., Pan, H., Wu, Y. & Zhu, F. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need. *Signal Transduction and Targeted Therapy* **6,** 48, doi:10.1038/s41392-021-00481-y (2021).

19 Feng, S. *et al.* Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nature Medicine,* doi:10.1038/s41591-021-01540-1 (2021).

20 Powell, A. A. *et al.* Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England. *Eurosurveillance* **26,** 2100634, doi:10.2807/1560-7917.es.2021.26.28.2100634 (2021).

21 Li, X. *et al.* Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. *BMJ* **373,** n1435, doi:10.1136/bmj.n1435 (2021).

22 Guidelines for Preparing Core Clinical-Safety Information on Drugs, Second Edition, Report of CIOMS Working Group III and V. [https://cioms.ch/wp-content/uploads/2018/03/Guidelines-for-Preparing-Core-Clinical-Safety-Info-Drugs-Report-of-CIOMS-Working-Group-III-and-V.pdf](https://cioms.ch/wp-content/uploads/2018/03/Guidelines-for-Preparing-Core-Clinical-Safety-Info-Drugs-Report-of-CIOMS-Working-Group-III-and-V.pdf) (2001).

23 Gargano, J. W. *et al.* Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. *MMWR Morb Mortal Wkly Rep* **70,** 977-982, doi:10.15585/mmwr.mm7027e2 (2021).

24 Xie, J. *et al.* Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes. *Jama* **326,** 1504-1515, doi:10.1001/jama.2021.15255 (2021).

25 Català, M. *et al.* “Analysis of new variants of SARS-CoV-2 in the Barcelona city and Northern Metropolitan area: success of the Delta and sinking of the B.1621 and the Gamma.” In: Analysis and prediction of COVID-19 for EU-EFTA-UK and other countries, #260. Research Report. pp. 10-14. Universitat Politècnica de Catalunya. 2021. Accessible at: [https://upcommons.upc.edu/handle/2117/355116](https://upcommons.upc.edu/handle/2117/355116)

26 Domínguez-Berjón, M. F. *et al.* [Constructing a deprivation index based on census data in large Spanish cities(the MEDEA project)]. *Gac Sanit* **22,** 179-187, doi:10.1157/13123961 (2008).

27 García-Gil, M. *et al.* Linking of primary care records to census data to study the association between socioeconomic status and cancer incidence in Southern Europe: a nation-wide ecological study. *PLoS One* **9,** e109706, doi:10.1371/journal.pone.0109706 (2014).

28 Nguyen, T. L. *et al.* Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. *BMC Med Res Methodol* **17,** 78, doi:10.1186/s12874-017-0338-0 (2017).

Methods
**Study design and data sources**

We performed a cohort study based on linked routinely collected data available to the Public Health Secretariat of Catalonia. Vaccine exposure was obtained from the Catalan Shared Clinical Records, a database with vaccine data covering the entire Catalan health system and all its vaccination centres. Additional linked data were obtained from the Catalan database of reverse transcription polymerase chain reaction (RT-PCR) tests and lateral flow tests (LFT) for SARS-CoV-2, from primary-care electronic health records, and from a population-based administrative hospital admissions data (CMBD-AH for its acronym in Catalan language). Data from these linked databases have previously been used for multiple COVID-19 research studies and include information for nearly 90% of the Catalan population.

**Participants, cohorts, and follow-up**

For our primary analysis, we included all individuals aged 19-59 years old who received a first dose of the ChAdOx1 vaccine and a second dose of ChAdOx1 (homologous vaccination) or BNT162b2 (heterologous vaccination). We followed participants from the day they received their second dose of either vaccine until an outcome, death, or the end of the study (13th October 2021).

We excluded people with a previous SARS-CoV-2 infection identified by a positive RT-PCR test or LFT and people assigned to one of the 10% of primary-care practices not contributing to our database.

Each participant receiving heterologous vaccination was matched 1:1 to one person receiving homologous vaccination using exact matching by age, sex, general practice centre, and date of second dose. In a sensitivity analysis, we changed the matching ratio to 1:2 and 1:5 to increase sample size.

**Study outcomes**

The primary outcome for effectiveness analyses was SARS-CoV-2 infection, defined by the date of the earliest of a positive RT-PCR test or LFT, regardless of symptoms or clinical diagnosis. We measured the number of tests over time regardless of results as an additional outcome to account for diagnostic effort.

Safety outcomes included venous thromboembolism, venous thromboembolism with thrombocytopenia, and myopericarditis within 21 days after the second vaccine dose, based on ChAdOx1 and BNT162b2 safety reports. Supplementary Table S2 includes the ICD-10-CM codes (international classification of diseases, 10th revision, clinical modification) used to ascertain when these events occurred.

We analysed the occurrence of a negative control outcome – low back pain – to identify potential unmeasured confounding. Negative control outcomes are health events not causally associated with the exposure of interest, here vaccination.

**Additional covariates**

Covariates used for confounding assessment included socio-demographics and clinical features assessed at the time of inclusion (day of the second vaccination), as recorded in primary care electronic health records and linked administrative data: age (in years), sex, area of residence, rurality and socioeconomic status,
number of RT-PCR tests or LFT performed, pre-existing comorbidities, and long-term medicine use. Supplementary Table 1 provides ICD-10-CM codes for comorbidities and Anatomical Therapeutic Chemical Classification (ATCC) codes used to identify previous medicine use. We assessed socioeconomic status using a validated deprivation index based on census data (MEDEA deprivation index)\textsuperscript{26,27}. Rurality of residence was measured, with rural areas defined by a population <10,000 inhabitants and a density <150 inhabitants/km\textsuperscript{2}, as per regional guidance.

Statistical analysis

Exact matching (1:1) between heterologous ChAdOx1/BNT162b2 vaccination and homologous two-dose ChAdOx1 was performed using the following variables: age (+/- 2 years), sex, general practice centre, and day of the second vaccination (+/- 2 days). As a sensitivity analysis, we generated additional study populations and repeated all analyses after matching with 1:2 and 1:5 ratios. We assessed confounding due to known variables by measuring covariate imbalance as the standardised mean difference (SMD) of all covariates listed above. We considered SMD>0.1 to be imbalanced\textsuperscript{28}.

We plotted time-to-event Kaplan-Meier estimates stratified by vaccine exposure (homologous vs heterologous). Absolute risk reduction (ARR) was estimated as the difference in cumulative incidence of Covid-19 amongst those receiving homologous - heterologous vaccination, and Number Needed to Treat (NNT) as 1/ARR. Cox regression models were then fitted to calculate hazard ratios and 95% confidence intervals for each of the study outcomes, according to vaccination schedule. Visual inspection of Schoenfeld residuals against the transformed time was used to evaluate the proportionality of hazards. A zero-inflated negative binomial regression model was used to calculate the incident rate ratio and 95% confidence interval for the number of tests.

All analyses were conducted using R version 4.0.0.

Tables

Table 1. Baseline characteristics of study participants stratified by vaccination schedule
| Variable                                      | Heterologous | Homologous |
|----------------------------------------------|--------------|------------|
| N                                            | 14,325       | 14,325     |
| **Socio-demographic and socio-economic**      |              |            |
| Mean (SD) age, years                         | 42.20 (9.60) | 42.21 (9.57) |
| Female sex                                   | 8,959 (62.5%)| 8,959 (62.5%) |
| Socioeconomic status: first quartile (least deprived) | 2,725 (19.02%) | 2,745 (19.16%) |
| Socioeconomic status: second quartile        | 4,403 (30.74%)| 4,363 (30.46%) |
| Socioeconomic status: third quartile         | 2,162 (15.09%)| 2,145 (14.97%) |
| Socioeconomic status: fourth quartile (most deprived) | 2,260 (15.78%) | 2,276 (15.89%) |
| Residence in a rural area                    | 2,775 (19.37%)| 2,796 (19.52%) |
| **Medicines use**                            |              |            |
| Analgesics                                   | 654 (4.57%)  | 533 (3.72%) |
| Sedatives/hypnotics                          | 1,049 (7.32%)| 948 (6.62%) |
| Anticoagulants                               | 201 (1.40%)  | 116 (0.81%) |
| Antidepressants                              | 1,228 (8.57%)| 1,077 (7.52%) |
| Antiepileptics                               | 449 (3.13%)  | 353 (2.46%) |
| Antipsychotics                               | 281 (1.96%)  | 157 (1.10%) |
| Antacids                                     | 618 (4.31%)  | 533 (3.72%) |
| Systemic corticosteroids                     | 101 (0.71%)  | 82 (0.57%)  |
| Oral antidiabetics                           | 187 (1.31%)  | 150 (1.05%) |
| Insulin                                      | 105 (0.73%)  | 73 (0.51%)  |
| Lipid modifying agents                       | 453 (3.16%)  | 410 (2.86%) |
| Alpha blockers                               | 5 (0.03%)    | 2 (0.01%)   |
| Other antihypertensives                      | 4 (0.03%)    | 1 (0.01%)   |
| Beta blockers                                | 202 (1.41%)  | 193 (1.35%) |
| Calcium channel blockers                     | 135 (0.94%)  | 101 (0.71%) |
| Combination antihypertensives                | 209 (1.46%)  | 176 (1.23%) |
| Diuretics                                    | 103 (0.72%)  | 108 (0.75%) |
| ACE inhibitors/ARBS                          | 423 (2.95%)  | 424 (2.96%) |
| Chronic obstructive pulmonary disease/asthma inhalers | 579 (4.04%)  | 528 (3.69%) |
| Comorbidities                                      | Incidence rate 1,000 person-years | Incidence rate 1,000 person-years |
|--------------------------------------------------|-----------------------------------|-----------------------------------|
| Atrial fibrillation                              | 23 (0.16%)                        | 19 (0.13%)                        |
| Osteoarthritis                                   | 513 (3.58%)                       | 533 (3.72%)                       |
| Asthma                                           | 935 (6.53%)                       | 910 (6.35%)                       |
| Ischaemic heart disease                          | 48 (0.34%)                        | 38 (0.27%)                        |
| Diabetes mellitus                                | 266 (1.86%)                       | 209 (1.46%)                       |
| Liver disease                                    | 289 (2.02%)                       | 278 (1.94%)                       |
| Hypertension                                     | 826 (5.77%)                       | 814 (5.68%)                       |
| Heart failure                                    | 5 (0.03%)                         | 2 (0.01%)                         |
| Cerebrovascular disease                          | 41 (0.29%)                        | 26 (0.18%)                        |
| Chronic obstructive pulmonary disease            | 46 (0.32%)                        | 37 (0.26%)                        |
| Chronic kidney disease                           | 44 (0.31%)                        | 54 (0.38%)                        |
| Cancer (all except non-melanoma skin cancer)     | 344 (2.40%)                       | 325 (2.27%)                       |
| Obesity                                          | 1,539 (10.74%)                    | 1,391 (9.71%)                     |
| Valvular disease                                 | 73 (0.51%)                        | 64 (0.45%)                        |
| Hepatitis B                                      | 20 (0.14%)                        | 15 (0.10%)                        |
| Hepatitis C                                      | 49 (0.34%)                        | 34 (0.24%)                        |
| HIV infection                                    | 49 (0.34%)                        | 47 (0.33%)                        |

Table 2. Number and incidence rate (per 1,000 person-years) of tests and SARS-CoV-2 infection (positive test) following second-dose vaccination, stratified by vaccination schedule
### Table 3. Number (%) of safety events in the 21 days following second dose, according to vaccination schedule

|                  | Heterologous | Homologous | HR/IRR  |
|------------------|--------------|------------|---------|
|                  | 1:1 matching | 1:2 matching | 1:5 matching | 1:1 matching | 1:2 matching | 1:5 matching |
| N participants   | 14,325       | 12,512     | 8,569    | 14,325       | 25,024       | 42,845       |
| N (%) of venous thromboembolism events | 1           | 1          | 1        | 0            | 0            | 0            |
| N (%) of venous thromboembolism with thrombocytopenia | 1           | 1          | 1        | 0            | 0            | 0            |
| N (%) of myopericarditis | 0          | 0          | 0        | 0            | 0            | 1            |

CI: confidence interval, HR: hazard ratio, IR: incidence rate, IRR: incident rate ratio, N: number, py: person-years, SD: Standard deviation
Figures

Figure 1

Population flowchart
Figure 2

Vaccine uptake and testing rates stratified by vaccination schedule
Figure 3

Kaplan-Meier plot of COVID-19 infection (primary outcome) after second-dose vaccination, stratified by vaccination schedule

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SUPPLEMENTARYFIGURESANDTABLES.docx